Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024

Abstract Aim The “Real‐World Multicenter Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes in China” (iCaReMe China) aims to generate contemporary evidence in Chinese type 2 diabetes mellitus (T2DM) patients. Materials and methods This is a prospective, observational, multicentric registry study with 19 000 subjects from 110 hospitals recruited in China. Adults diagnosed with T2D and/or hypertension (HTN) (combined chronic kidney disease [CKD]), and/or heart failure (HF) and/or CKD were included. Data were collected every 6 months. Results In this article, we reported the findings from the baseline T2DM cohort, comprising 9000 patients recruited from 60 hospitals. The mean HbA1c level was 8.5 ± 2.2%, with 29.0% of them achieving the target HbA1c goal of <7.0%. The average blood pressure was 131/81 mmHg, with merely 27.8% reaching the target goal of blood pressure below 130/80 mmHg. The mean concentration of low‐density lipoprotein cholesterol (LDL‐C) was 2.8 ± 1.0 mmol/L, with 43.0% of the patients achieving an LDL‐C level below 2.6 mmol/L. Only 5.0% of the patients achieved all three control targets for HbA1c, blood pressure and LDL‐C. Conclusion The registry demonstrated suboptimal control rates for cardiovascular risk factors among Chinese T2DM patients, underscoring the imperative need for implementing guideline‐directed management.